568 results on '"Chiron, C"'
Search Results
152. Cortical auditory-evoked responses in preterm neonates: Revisited by spectral and temporal analyses
- Author
-
Kaminska A., Delattre V., Laschet J., Dubois J., Labidurie M., Duval A., Manresa A., Magny J., Hovhannisyan S., Mokhtari M., Ouss L., Boissel A., Hertz-Pannier L., Sintsov M., Minlebaev M., Khazipov R., Chiron C., Kaminska A., Delattre V., Laschet J., Dubois J., Labidurie M., Duval A., Manresa A., Magny J., Hovhannisyan S., Mokhtari M., Ouss L., Boissel A., Hertz-Pannier L., Sintsov M., Minlebaev M., Khazipov R., and Chiron C.
- Abstract
© The Author 2017. Published by Oxford University Press. Characteristic preterm EEG patterns of "Delta-brushes" (DBs) have been reported in the temporal cortex following auditory stimuli, but their spatio-temporal dynamics remains elusive. Using 32-electrode EEG recordings and co-registration of electrodes' position to 3D-MRI of age-matched neonates, we explored the cortical auditory-evoked responses (AERs) after 'click' stimuli in 30 healthy neonates aged 30-38 post-menstrual weeks (PMW). (1) We visually identified auditory-evoked DBs within AERs in all the babies between 30 and 33 PMW and a decreasing response rate afterwards. (2) The AERs showed an increase in EEG power from delta to gamma frequency bands over the middle and posterior temporal regions with higher values in quiet sleep and on the right. (3) Time-frequency and averaging analyses showed that the delta component of DBs, which negatively peaked around 550 and 750 ms over the middle and posterior temporal regions, respectively, was superimposed with fast (alpha-gamma) oscillations and corresponded to the late part of the cortical auditory-evoked potential (CAEP), a feature missed when using classical CAEP processing. As evoked DBs rate and AERs delta to alpha frequency power decreased until full term, auditory-evoked DBs are thus associated with the prenatal development of auditory processing and may suggest an early emerging hemispheric specialization.
153. Auditory stimuli mimicking ambient sounds drive temporal 'delta-brushes' in premature infants
- Author
-
Chipaux M., Colonnese M., Mauguen A., Fellous L., Mokhtari M., Lezcano O., Milh M., Dulac O., Chiron C., Khazipov R., Kaminska A., Chipaux M., Colonnese M., Mauguen A., Fellous L., Mokhtari M., Lezcano O., Milh M., Dulac O., Chiron C., Khazipov R., and Kaminska A.
- Abstract
In the premature infant, somatosensory and visual stimuli trigger an immature electroencephalographic (EEG) pattern, "delta-brushes," in the corresponding sensory cortical areas. Whether auditory stimuli evoke delta-brushes in the premature auditory cortex has not been reported. Here, responses to auditory stimuli were studied in 46 premature infants without neurologic risk aged 31 to 38 postmenstrual weeks (PMW) during routine EEG recording. Stimuli consisted of either low-volume technogenic "clicks" near the background noise level of the neonatal care unit, or a human voice at conversational sound level. Stimuli were administrated pseudo-randomly during quiet and active sleep. In another protocol, the cortical response to a composite stimulus ("click" and voice) was manually triggered during EEG hypoactive periods of quiet sleep. Cortical responses were analyzed by event detection, power frequency analysis and stimulus locked averaging. Before 34 PMW, both voice and "click" stimuli evoked cortical responses with similar frequency-power topographic characteristics, namely a temporal negative slow-wave and rapid oscillations similar to spontaneous delta-brushes. Responses to composite stimuli also showed a maximal frequency-power increase in temporal areas before 35 PMW. From 34 PMW the topography of responses in quiet sleep was different for "click" and voice stimuli: responses to "clicks" became diffuse but responses to voice remained limited to temporal areas. After the age of 35 PMW auditory evoked delta-brushes progressively disappeared and were replaced by a low amplitude response in the same location. Our data show that auditory stimuli mimicking ambient sounds efficiently evoke delta-brushes in temporal areas in the premature infant before 35 PMW. Along with findings in other sensory modalities (visual and somatosensory), these findings suggest that sensory driven delta-brushes represent a ubiquitous feature of the human sensory cortex during fetal stages an
154. Auditory stimuli mimicking ambient sounds drive temporal 'delta-brushes' in premature infants
- Author
-
Chipaux M., Colonnese M., Mauguen A., Fellous L., Mokhtari M., Lezcano O., Milh M., Dulac O., Chiron C., Khazipov R., Kaminska A., Chipaux M., Colonnese M., Mauguen A., Fellous L., Mokhtari M., Lezcano O., Milh M., Dulac O., Chiron C., Khazipov R., and Kaminska A.
- Abstract
In the premature infant, somatosensory and visual stimuli trigger an immature electroencephalographic (EEG) pattern, "delta-brushes," in the corresponding sensory cortical areas. Whether auditory stimuli evoke delta-brushes in the premature auditory cortex has not been reported. Here, responses to auditory stimuli were studied in 46 premature infants without neurologic risk aged 31 to 38 postmenstrual weeks (PMW) during routine EEG recording. Stimuli consisted of either low-volume technogenic "clicks" near the background noise level of the neonatal care unit, or a human voice at conversational sound level. Stimuli were administrated pseudo-randomly during quiet and active sleep. In another protocol, the cortical response to a composite stimulus ("click" and voice) was manually triggered during EEG hypoactive periods of quiet sleep. Cortical responses were analyzed by event detection, power frequency analysis and stimulus locked averaging. Before 34 PMW, both voice and "click" stimuli evoked cortical responses with similar frequency-power topographic characteristics, namely a temporal negative slow-wave and rapid oscillations similar to spontaneous delta-brushes. Responses to composite stimuli also showed a maximal frequency-power increase in temporal areas before 35 PMW. From 34 PMW the topography of responses in quiet sleep was different for "click" and voice stimuli: responses to "clicks" became diffuse but responses to voice remained limited to temporal areas. After the age of 35 PMW auditory evoked delta-brushes progressively disappeared and were replaced by a low amplitude response in the same location. Our data show that auditory stimuli mimicking ambient sounds efficiently evoke delta-brushes in temporal areas in the premature infant before 35 PMW. Along with findings in other sensory modalities (visual and somatosensory), these findings suggest that sensory driven delta-brushes represent a ubiquitous feature of the human sensory cortex during fetal stages an
155. Epilepsies myocloniques des encephalopathies non progressives avec etats de mal myocloniques
- Author
-
Chiron, C., primary, Plouin, P., additional, Dulac, O., additional, Mayer, M., additional, and Ponsot, G., additional
- Published
- 1988
- Full Text
- View/download PDF
156. Caracteres electrocliniques des crises dans le syndrome d'Aicardi
- Author
-
BOUR, F, primary, CHIRON, C, additional, DULAC, O, additional, and PLOUIN, P, additional
- Published
- 1986
- Full Text
- View/download PDF
157. Etude du debit sanguin cerebral dans le syndrome de west idiopathique: correlation avec les donnees electroencephalographiques
- Author
-
DULAC, O, primary, RAYNAUD, C, additional, CHIRON, C, additional, PLOUIN, P, additional, SYROTA, A, additional, and ARTHUIS, M, additional
- Published
- 1987
- Full Text
- View/download PDF
158. Hemimegalencephaly: MR imaging in five children.
- Author
-
Kalifa, G L, primary, Chiron, C, additional, Sellier, N, additional, Demange, P, additional, Ponsot, G, additional, Lalande, G, additional, and Robain, O, additional
- Published
- 1987
- Full Text
- View/download PDF
159. Enregistrement ambulatoire de l'EEG pendant 24 heures dans les spasmes infantiles epileptiques
- Author
-
PLOUIN, P, primary, JALIN, C, additional, DULAC, O, additional, and CHIRON, C, additional
- Published
- 1987
- Full Text
- View/download PDF
160. Single-photon emission computed tomography: ictal perfusion in childhood epilepsies
- Author
-
Chiron, C., Vera, P., Kaminska, A., Hollo, A., Cieuta, C., Ville, D., and Dulac, O.
- Published
- 1999
- Full Text
- View/download PDF
161. Maturational Changes of Regional Blood Flow in Children During the First 20 Months of Life.
- Author
-
Tzourio, N., Chiron, C., Raynaud, C., Zilbovicius, M., Dulac, O., Mazoyer, B., Bourguignon, M., and Syrota, A.
- Published
- 1989
162. Triangular test (TT), a sequential approach for comparative trials in children.
- Author
-
Pons, G., Hulot, J., Treluyer, J., Chiron, C., Tonnelier, S., and Lechat, P.
- Published
- 2004
- Full Text
- View/download PDF
163. Imaging techniques of the CNS of the neonates, J Haddad, D Christmann, J Messer. Springer-Verlag (1991)
- Author
-
Chiron, C
- Published
- 1993
- Full Text
- View/download PDF
164. Diagnostic Value of Regional Cerebral Blood Flow Imaging by SPECT in Sturge-Weber Angiomatosis.
- Author
-
Chiron, C., Raynaud, C., Tzourio, N., Dulac, O., Diebler, C., and Syrota, A.
- Published
- 1989
165. Regional Cerebral Blood Flow Measured by SPECT Before and After Stimulation in Developmental Dysphasia.
- Author
-
Raynaud, C., Billard, C., Tzourio, N., Chiron, C., Zilbovicius, M., Dulac, O., Mazoyer, B., Bourguignon, M., and Syrota, A.
- Published
- 1989
166. Longitudinal Study of Regional Cerebral Blood Flow in Partial Epilepsy of Childhood After Cessation of Seizures.
- Author
-
Chiron, C., Jambaqué, I., Raynaud, C., Tzourio, N., Zilbovicius, M., Dulac, O., and Syrota, A.
- Published
- 1989
167. Diagnostic Value of Regional Cerebral Blood Flow Imaging by SPECT in SturgeWeber Angiomatosis
- Author
-
Chiron, C., Raynaud, C., Tzourio, N., Dulac, O., Diebler, C., and Syrota, A.
- Published
- 1989
168. Lunar simulant behaviour in molten fluoride salt for ISRU applications.
- Author
-
Maes, M., Gibilaro, M., Chamelot, P., Chiron, C., Chevrel, S., Pinet, P., Massot, L., and Favier, J.J.
- Subjects
- *
FUSED salts , *REGOLITH , *ALUMINUM oxide , *METALLIC oxides , *ATOMIC emission spectroscopy , *FERRIC oxide , *LUNAR soil - Abstract
This study investigated the behaviour of a lunar mare crystalline analog dissolved in molten LiF–NaF at 800 °C for the in situ production of metals as a part of In Situ Resource Utilization (ISRU) research. Molten fluorides have the capability to dissolve metallic oxides, and the Hall-Héroult process uses this kind of media to produce Al from Al 2 O 3.The first step was to compare the individual solubility of the main oxides composing the mare lunar soil (SiO 2 , Al 2 O 3 , Fe 2 O 3 , and MgO) with the solubility of the crystalline analog using Inductively Coupled Plasma – Atomic Emission Spectroscopy (ICP-AES). The species concentration added jointly are lower than the concentration of the same species added separately. Nonetheless, this study showed that LiF–NaF can be used to dissolve the analog with a maximum solubility of 3.9 wt% at 800 °C. Cyclic voltammograms were also used to verify the electroactivity of all oxide species in LiF–NaF, wherein all the main oxides are electroactive except SiO 2 and TiO 2. Then electrolyses on different cathodic substrates were performed at different conditions and the obtained cathodic products were analysed with a scanning electron microscope (SEM) coupled with an energy dispersive spectroscopy (EDS). Despite the non-electroactivity of SiO 2 and TiO 2 , they were extracted in an alloyed form through Under Potential Deposition (UPD). Metallic deposition of other metals such as aluminium and titanium was achieved on carbon electrode. Finally, a synthetic mixture made of the different oxide species with the same chemical composition as the simulant, was investigated as a viable substitute for lunar mare soil. Its electrochemical behaviour was identical to the crystalline lunar simulant showing that our original process based on oxides dissolution is not influenced by the amorphous/crystalline state of the raw material. the outputs of LiF–NaF molten process are not critically influenced by the physical state of the lunar regolith. • LiF-NaF at 800°C was used to dissolve a mare lunar analog (Basalt Pic d'Ysson). • All the oxides composing the natural lunar simulant are soluble. • Metallic deposits of Si-Mo and Si-Fe were obtained on Mo and Fe electrodes. • Any lunar simulant can be reproduced by mixing, with the appropriate chemical composition, the oxides together. • The oxides dissolution is not influenced by the amorphous/crystalline state of the raw material. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
169. Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines.
- Author
-
Ruggieri, L, Giannuzzi, V, Baiardi, P, Bonifazi, F, Davies, E H, Giaquinto, C, Bonifazi, D, Felisi, M, Chiron, C, Pressler, R, Rabe, H, Whitaker, M J, Neubert, A, Jacqz-Aigrain, E, Eichler, I, Turner, M A, Ceci, A, and GRiP Consortium
- Abstract
Unlabelled: The European Paediatric Regulation mandated the European Commission to fund research on off-patent medicines with demonstrated therapeutic interest for children. Responding to this mandate, five FP7 project calls were launched and 20 projects were granted. This paper aims to detail the funded projects and their preliminary results. Publicly available sources have been consulted and a descriptive analysis has been performed. Twenty Research Consortia including 246 partners in 29 European and non-European countries were created (involving 129 universities or public-funded research organisations, 51 private companies with 40 SMEs, 7 patient associations). The funded projects investigate 24 medicines, covering 10 therapeutic areas in all paediatric age groups. In response to the Paediatric Regulation and to apply for a Paediatric Use Marketing Authorisation, 15 Paediatric Investigation Plans have been granted by the EMA-Paediatric Committee, including 71 studies of whom 29 paediatric clinical trials, leading to a total of 7,300 children to be recruited in more than 380 investigational centres.Conclusion: Notwithstanding the EU contribution for each study is lower than similar publicly funded projects, and also considering the complexity of paediatric research, these projects are performing high-quality research and are progressing towards the increase of new paediatric medicines on the market. Private-public partnerships have been effectively implemented, providing a good example for future collaborative actions. Since these projects cover a limited number of off-patent drugs and many unmet therapeutic needs in paediatrics remain, it is crucial foreseeing new similar initiatives in forthcoming European funding programmes. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
170. Devastating epileptic encephalopathy in school-aged children (DESC): A pseudo encephalitis
- Author
-
Mikaeloff, Y., Jambaqué, I., Hertz-Pannier, L., Zamfirescu, A., Adamsbaum, C., Plouin, P., Dulac, O., and Chiron, C.
- Subjects
- *
EPILEPSY , *SEIZURES (Medicine) , *SPASMS , *CEREBRAL cortex - Abstract
Abstract: Purpose: To describe the characteristics of a previously overlooked devastating epileptic encephalopathy that presents as intractable bilateral perisylvian epilepsy starting with prolonged status epilepticus (SE) in normally developing school-aged children. Methods: Retrospective study over 7 years of all normally developing children admitted in our institution for a prolonged SE following non-specific febrile illness with at least one seizure recorded on EEG. Results: Fourteen children were included at a median age of 7.5 years (4–11) (median follow-up of 4 years (1–7)). Intractable SE lasted 4–60 days (median 30). CSF cell count was normal in five cases and moderately increased in the others. During SE, seizures were recorded in 11 patients and involved temporal lobes in 7; the other 4 patients exhibited perisylvian clinical features with secondary generalization. Intractable epilepsy followed SE in all cases without any latent period. Persisting seizures were recorded in 10 patients and involved temporo-perisylvian regions in 8, frontal regions in 2; 3 others had perisylvian ictal semiology. Spiking was bilateral in 10 cases. MRI showed bilateral hippocampal hypersignal and/or atrophy in 10 cases (extended to the neocortex in 3). All children had major cognitive sequelae. When feasible (six patients), detailed neuropsychology suggested fronto-temporal impairment. Conclusions: Among so called grey matter encephalitis patients, we identified a recognizable pattern we propose to call Devastating Epileptic encephalopathy in School-age Children (DESC) that begins with prolonged SE triggered by fever of unknown cause, and persists as intractable perisylvian epilepsy with severe cognitive deterioration. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
171. Acceptabilité et tolérance du valproate de sodium, granules à libération prolongée, en monothérapie chez l'enfant épileptique à partir de trois ans
- Author
-
Motte, J., Pedespan, J.M., Sevestre, M., and Chiron, C.
- Subjects
- *
VALPROIC acid , *ANTICONVULSANTS , *CHILDREN , *THERAPEUTICS , *CHILDREN with epilepsy - Abstract
Abstract: Sodium valproate (VPA) is an anti-epileptic drug which was until now administered to children as drinkable or injectable form. A new galenic form of this compound has been developed as microgranules with prolonged release (Micropakine®LP; MPK). This new galenic form of VPA allows a greater stability of the plasmatic rates, thus limiting the risk of amount-dependent adverse effects at the time of the peaks, and of less effectiveness at the time of the fall of the circulating rates. The main objective of this study was to evaluate the acceptability of the new galenic form of VPA, in monotherapy, for epileptic children with ≥3 years old. The evaluation was performed at day (D)90 by the patients using a hedonic visual scale. The secondary objectives were to evaluate the acceptability by the parents, the treatment compliance, the percentage of patients free of seizure at D 90, and the tolerance. Finally, the authors compared all these data to those recovered at the baseline in patients already treated by the previous drinkable VPA. A total of 307 patients were involved by 76 hospital neuropediatric physicians. The population was constituted by 110 children <5 years old and 197 children from 5 to 14 years old. MPK was well accepted for total population at D 90 (<5 years old: 83.3%; ≥5 years old: 80%). For patients previously treated by drinkable form of VPA (N =199), MPK was significantly better accepted than the drinkable form at D1 (<5 years, P =0.0189; ≥5 years, P <0.0001). Less difficulties were experienced by the parents to administrate MPK when compared to the drinkable form (P <0.001), mainly due to his neutral taste. Patients free of seizure at D 90 were 77% [70,3; 82,5]. Specially, fewer epileptic seizures were evidenced for all children previously treated at D1 by drinkable form of VPA. The treatment was well respected by the patients, which were compliant in 80% of the cases. The adherence to treatment was good since the treatment compliance was 87%. MPK was well tolerated. Conclusion. – MPK in the microgranule form significantly improves the treatment acceptability with a good tolerance. Two daily intakes and neutral taste are two major advantages to favour the compliance in children, thus contributing to the efficacy of the antiepileptic treatment. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
172. L'épilepsie dans les aberrations chromosomiques
- Author
-
Bahi-Buisson, N., Ville, D., Eisermann, M., Plouin, P., Kaminska, A., and Chiron, C.
- Subjects
- *
EPILEPSY , *DEVELOPMENTAL disabilities , *CHROMOSOME abnormalities , *ELECTROENCEPHALOGRAPHY , *ANGELMAN syndrome , *HUMAN chromosome 15 abnormalities - Abstract
Abstract: Epilepsy is among the most frequent finding in many chromosome aberrations. While most chromosome aberrations can be associated with different seizure types, there are few aberrations which feature specific seizures and EEG patterns. Among the 400 different chromosomal imbalances described with seizures and EEG abnormalities, eight have a high association with epilepsy. These comprise: the monosomy 1p36, Wolf-Hirschhorn syndrome (4p-), Angelman syndrome, Miller-Dieker del 17p13.3, the inversion duplication 15 syndrome, ring 20 and ring 14 syndromes, Down’s syndrome. These chromosomal regions where aberrations have an evident association with epilepsy may be useful targets for gene hunters. On the other hand, a better characterisation of epileptic syndrome in these disorders may lead to a better and specific treatment. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
173. Absence of mutations in major GEFS+ genes in myoclonic astatic epilepsy
- Author
-
Nabbout, R., Kozlovski, A., Gennaro, E., Bahi-Buisson, N., Zara, F., Chiron, C., Bianchi, A., Brice, A., Leguern, E., and Dulac, O.
- Subjects
- *
LENNOX-Gastaut syndrome , *GENETICS , *GENETIC mutation , *SPASMS - Abstract
Myoclonic astatic epilepsy (MAE) is a genetically determined condition of childhood onset characterized by multiple generalized types of seizures including myoclonic astatic seizures, generalized spike waves and cognitive deterioration. This condition has been reported in a few patients in generalized epilepsy with febrile seizures plus (GEFS+) families and MAE has been considered, like severe myoclonic epilepsy of infancy (SMEI), to be a severe phenotype within the GEFS+ spectrum. Four genes have been identified in GEFS+ families, but only three (SCN1A, SCNlB, GABRG2) were found in MAE patients within GEFS+ families.We analysed these three genes in a series of 22 sporadic patients with MAE and found no causal mutations. These findings suggest that MAE, unlike SMEI, is not genetically related to GEFS+. Although MAE and SMEI share the same types of seizures, only SMEI patients are sensitive to fever. This is probably its main link to GEFS+. A different family of genes is likely to account for MAE. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
174. Infantile spasms in Down syndrome—effects of delayed anticonvulsive treatment
- Author
-
Eisermann, Monika Maria, DeLaRaillère, A., Dellatolas, G., Tozzi, E., Nabbout, R., Dulac, O., and Chiron, C.
- Subjects
- *
EPILEPSY , *ETIOLOGY of diseases , *PATIENTS - Abstract
To investigate the impact of treatment lag in infantile spasms (IS) on treatment response, occurrence of later epilepsy, and long-term cognition and behavior in patients with one single etiological entity, we examined 18 patients with Down syndrome (DS) and earlier IS retrospectively (follow-up period of 32–180 months with a mean of 85.1 months), and determined their history and present condition, in terms of previously mentioned items. There was a statistically significant correlation between treatment lag and lag to cessation of spasms (
R=0.55 ,P=0.02 ), developmental quotient (DQ) (R=−0.75 ,P=0.003 ), and score of autistic features (AF) (R=0.57 ,P=0.04 ). Moreover we found that the later the response to treatment of IS, the lower was the DQ (R=−0.86 ,P=0.001 ) and the higher was the score of autistic features (R=0.5 ,P=0.06 ). A long duration of spasms also determined a low DQ (R=−0.93 ,P<0.0001 ) and a high score of autistic features (R=0.66 ,P<0.01 ). All patients with persistent epilepsy (n=5 ) had had a treatment lag of over 2 months. Conversely, for all children treated within 2 months (n=8 ) spasms ceased within 3 months of treatment and none of them had later epilepsy. This group of patients with a treatment lag of less than 2 months had earlier treatment response (P=0.002 ), higher DQ (P=0.004 ) and lower score of autistic features (P=0.006 ). The data stress the importance of a short treatment lag in view of mental development and prevention of later epilepsy and autistic features, and raise the question of antiepileptogenic effect in this specific condition. [Copyright &y& Elsevier]- Published
- 2003
- Full Text
- View/download PDF
175. In-situ electrochemical oxide monitoring in LiF-NdF3-Nd2O3: Application to Nd2O3 solubility determination.
- Author
-
Remazeilles, C., Gibilaro, M., Massot, L., Chiron, C., Martinez, A.M., and Chamelot, P.
- Subjects
- *
ELEMENTAL analysis , *PLATINUM electrodes , *RARE earth oxides , *SQUARE waves , *OXIDES , *ELECTROLYSIS - Abstract
• Use of square wave voltammetry in LiF-NdF 3 -Nd 2 O 3 to evidence the oxide oxidation into O 2. • A calibration curve to monitor the in-situ oxide content was obtained. • Oxide solubility determination at different temperatures verified by elemental oxygen analysis. • In-situ electrochemical method for oxide monitoring in LiF-NdF 3 -Nd 2 O 3 is proposed. Neodymium oxide titration was investigated in the LiF-NdF 3 -Nd 2 O 3 melt on platinum electrode by square wave voltammetry (SWV) in order to develop an in-situ and fast technique for oxide amount monitoring during Nd or Nd-Fe production by electrolysis. The methodology was verified by elemental analyses in the 850–1050 °C temperature range and then applied to Nd 2 O 3 solubility determination in LiF-NdF 3. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
176. Essai randomisé hydrocortisone vs vigabatrin en monothérapie de première intention dans les spasmes infantiles de la maladie de Bourneville
- Author
-
Chiron, C., Durnas, C., Motte, J., Allaire, Besson-Leaud, Damon, Danel, Derambure, Parisot, Pascal, and Dulac, O.
- Published
- 1995
- Full Text
- View/download PDF
177. Inhibitory effect of (L) carnitine on octanoate oxidation in isolated rat liver mitochondria
- Author
-
Chiron, C., Catelloni, F., Cinquin, F., Roth, H., and Leverve, X.
- Published
- 1991
- Full Text
- View/download PDF
178. 185 pHaddadJChristmannDMesserJImaging techniques of the CNS of the neonates1991Springer-VerlagParis
- Author
-
Chiron, C
- Published
- 1993
- Full Text
- View/download PDF
179. Fgf17: A regulator of the mid/hind brain boundary in mammals.
- Author
-
Oberholzer Z, Loubser C, and Nikitina NV
- Abstract
The Fibroblast growth factor (FGFs) family consists of at least 22 members that exert their function by binding and activating fibroblast growth factor receptors (FGFRs). The Fgf8/FgfD subfamily member, Fgf17, is located on human chromosome 8p21.3 and mouse chromosome 14 D2. In humans, FGF17 can be alternatively spliced to produce two isoforms (FGF17a and b) whereas three isoforms are present in mice (Fgf17a, b, and c), however, only Fgf17a and Fgf17b produce functional proteins. Fgf17 is a secreted protein with a cleavable N-terminal signal peptide and contains two binding domains, namely a conserved core region and a heparin binding site. Fgf17 mRNA is expressed in a wide range of different tissues during development, including the rostral patterning centre, midbrain-hindbrain boundary, tailbud mesoderm, olfactory placode, mammary glands, and smooth muscle precursors of major arteries. Given its broad expression pattern during development, it is surprising that adult Fgf17
-/- mice displayed a rather mild phenotype; such that mutants only exhibited morphological changes in the frontal cortex and mid/hind brain boundary and changes in certain social behaviours. In humans, FGF17 mutations are implicated in several diseases, including Congenital Hypogonadotropic Hypogonadism and Kallmann Syndrome. FGF17 mutations contribute to CHH/KS in 1.1% of affected individuals, often presenting in conjunction with mutations in other FGF pathway genes like FGFR1 and FLRT3. FGF17 mutations were also identified in patients diagnosed with Dandy-Walker malformation and Pituitary Stalk Interruption Syndrome, however, it remains unclear how FGF17 is implicated in these diseases. Altered FGF17 expression has been observed in several cancers, including prostate cancer, hematopoietic cancers (acute myeloid leukemia and acute lymphoblastic leukemia), glioblastomas, perineural invasion in cervical cancer, and renal cell carcinomas. Furthermore, FGF17 has demonstrated neuroprotective effects, particularly during ischemic stroke, and has been shown to improve cognitive function in ageing mice., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
180. Additional Results from Two Randomized, Placebo-Controlled Trials of Stiripentol in Dravet Syndrome Highlight a Rapid Antiseizure Efficacy with Longer Seizure-Free Periods.
- Author
-
Guerrini R, Chancharme L, Serraz B, and Chiron C
- Abstract
Introduction: The efficacy of stiripentol in Dravet syndrome children was evidenced in two randomized, double-blind, placebo-controlled, phase 3 studies, namely STICLO France (October 1996-August 1998) and STICLO Italy (April 1999-October 2000), but data were not fully exploited at the time., Methods: This post-hoc analysis used additional information, notably collected during the open-label extension (OLE) month, or reported by caregivers in individual diaries, to evaluate new outcomes., Results: Overall, 64 patients were included (31 in the placebo group, 33 in the stiripentol group) of whom 34 (53.1%) were female. Patients' mean and median (25%; 75%) age were 9.2 years (range 3.0-20.7 years) and 8.7 years (6.0; 12.1) respectively. At the end of the double-blind treatment period, 72% of the patients in the stiripentol group had a ≥ 50% decrease in generalized tonic-clonic seizure (GTCS) frequency, versus 7% in the placebo group (P < 0.001), 56% had a profound (≥ 75%) decrease versus 3% in the placebo group (P < 0.001), and 38% were free of GTCS, but none in the placebo group (P < 0.001). The onset of stiripentol efficacy was rapid, significant from the fourth day of treatment onwards. The median longest period of consecutive days with no GTCS was 32 days in the stiripentol group compared to 8.5 days in the placebo group (P < 0.001). Further to the switch to the third month OLE, an 80.2% decrease in seizure frequency from baseline was observed in patients previously receiving placebo, while no change in efficacy was observed in those already on stiripentol. Adverse events were more frequent in the stiripentol group, with significantly more episodes of somnolence, anorexia, and weight decrease than in the placebo group., Conclusion: Altogether these new analyses of the STICLO data reinforce the evidence for a remarkable efficacy of stiripentol in Dravet syndrome, with a demonstrated rapid onset of action and sustained response, as also evidenced in further post-randomized trials., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
181. Brain 18 F-FDG PET reveals cortico-subcortical hypermetabolic dysfunction in juvenile neuropsychiatric systemic lupus erythematosus.
- Author
-
Rodrigo S, Costi S, Ellul P, Aubart M, Boddaert N, Auvin S, Elmaleh M, Ntorkou A, Bader-Meunier B, Lebon V, Melki I, and Chiron C
- Abstract
Background: In juvenile systemic lupus erythematosus (j-SLE) with neuropsychiatric (NP) symptoms, there is a lack of diagnostic biomarkers. Thus, we study whether PET-FDG may identify any metabolic dysfunction in j-NPSLE., Methods: A total of 19
18 FDG-PET exams were consecutively performed using PET-MRI system in 11 non-sedated patients presenting with j-NPSLE (11-18y) for less than 18 months (m) and without any significant lesion at MRI. Psychiatric symptoms were scored from 0 (none) to 3 (severe) at PET time. PET images were visually analyzed and voxel-based analyses of cerebral glucose metabolism were performed using statistical parametric mapping (spm) with an age-matched control group, at threshold set > 50 voxels using both p < 0.001 uncorrected (unc.) and p < 0.05 corrected family wise error (FWE)., Results: Patients exhibited mainly psychiatric symptoms, with diffuse inflammatory j-NPSLE. First PET (n = 11) was performed at a mean of 15y of age, second/third PET (n = 7/n = 1) 6 to 19 m later. PET individual analysis detected focal bilateral anomalies in 13/19 exams visually but 19/19 using spm (unc.), mostly hypermetabolic areas (18/19). A total of 15% of hypermetabolic areas identified by spm had been missed visually. PET group analysis (n = 19) did not identify any hypometabolic area, but a large bilateral cortico-subcortical hypermetabolic pattern including, by statistical decreasing order (unc.), thalamus, subthalamic brainstem, cerebellum (vermis and cortex), basal ganglia, visual, temporal and frontal cortices. Mostly the subcortical hypermetabolism survived to FWE analysis, being most intense and extensive (51% of total volume) in thalamus and subthalamus brainstem. Hypermetabolism was strictly subcortical in the most severe NP subgroup (n = 8, scores 2-3) whereas it also extended to cerebral cortex, mostly visual, in the less severe subgroup (n = 11, scores 0-1), but difference was not significant. Longitudinal visual analysis was inconclusive due to clinical heterogeneity., Conclusions: j-NPSLE patients showed a robust bilateral cortico-subcortical hypermetabolic network, focused subcortically, particularly in thalamus, proportionally to psychiatric features severity. Further studies with larger, but homogeneous, cohorts are needed to determine the sensitivity and specificity of this dysfunctional pattern as a potential biomarker in diffuse inflammatory j-NPSLE with normal brain MRI., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
182. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
- Author
-
Guerrini R, Chiron C, Vandame D, Linley W, and Toward T
- Subjects
- Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Cannabidiol therapeutic use, Cannabidiol adverse effects, Cannabidiol administration & dosage, Epilepsies, Myoclonic drug therapy, Dioxolanes therapeutic use, Dioxolanes adverse effects, Fenfluramine therapeutic use, Fenfluramine adverse effects, Anticonvulsants therapeutic use, Anticonvulsants adverse effects, Network Meta-Analysis, Drug Therapy, Combination, Seizures drug therapy
- Abstract
Objectives: Stiripentol, fenfluramine, and cannabidiol are licensed add-on therapies to treat seizures in Dravet Syndrome (DS). There are no direct or indirect comparisons assessing their full licensed dose regimens, across different jurisdictions, as first-line add-on therapies in DS., Methods: We conducted a systematic review and frequentist network meta-analysis (NMA) of randomized controlled trial (RCT) data for licensed add-on DS therapies. We compared the proportions of patients experiencing: reductions from baseline in monthly convulsive seizure frequency (MCSF) of ≥50% (clinically meaningful), ≥75% (profound), and 100% (seizure-free); serious adverse events (SAEs); discontinuations due to AEs., Results: We identified relevant data from two placebo-controlled RCTs for each drug. Stiripentol 50 mg/kg/day and fenfluramine 0.7 mg/kg/day had similar efficacy in achieving ≥50% (clinically meaningful) and ≥75% (profound) reductions from baseline in MCSF (absolute risk difference [RD] for stiripentol versus fenfluramine 1% [95% confidence interval: -20% to 22%; p = 0.93] and 6% [-15% to 27%; p = 0.59], respectively), and both were statistically superior (p < 0.05) to licensed dose regimens of cannabidiol (10 or 20 mg/kg/day, with/irrespective of clobazam) for these outcomes. Stiripentol was statistically superior in achieving seizure-free intervals compared to fenfluramine (RD = 26% [CI: 8% to 44%; p < 0.01]) and licensed dose regimens of cannabidiol. There were no significant differences in the proportions of patients experiencing SAEs. The risk of discontinuations due to AEs was lower for stiripentol, although the stiripentol trials were shorter., Significance: This NMA of RCT data indicates stiripentol, as a first-line add-on therapy in DS, is at least as effective as fenfluramine and both are more effective than cannabidiol in reducing convulsive seizures. No significant difference in the incidence of SAEs between the three add-on agents was observed, but stiripentol may have a lower risk of discontinuations due to AEs. These results may inform clinical decision-making and the continued development of guidelines for the treatment of people with DS., Plain Language Summary: This study compared three drugs (stiripentol, fenfluramine, and cannabidiol) used alongside other medications for managing seizures in a severe type of epilepsy called DS. The study found that stiripentol and fenfluramine were similarly effective in reducing seizures and both were more effective than cannabidiol. Stiripentol was the best drug for stopping seizures completely based on the available clinical trial data. All three drugs had similar rates of serious side effects, but stiripentol had a lower chance of being stopped due to side effects. This information can help guide treatment choices for people with DS., (© 2024 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.)
- Published
- 2024
- Full Text
- View/download PDF
183. Pitfalls of using video-EEG for a trial endpoint in children aged <4 years with focal seizures.
- Author
-
Bozorg A, Beller C, Jensen L, Arzimanoglou A, Chiron C, Dlugos D, Gaitanis J, Wheless JW, and McClung C
- Subjects
- Child, Humans, Child, Preschool, Lacosamide therapeutic use, Reproducibility of Results, Treatment Outcome, Seizures diagnosis, Seizures drug therapy, Seizures chemically induced, Electroencephalography, Anticonvulsants, Epilepsies, Partial diagnosis, Epilepsies, Partial drug therapy
- Abstract
Objective: Double-blind, randomized, and placebo-controlled trial SP0967 (NCT02477839/2013-000717-20) did not demonstrate superior efficacy of lacosamide versus placebo in patients aged ≥1 month to <4 years with uncontrolled focal seizures, per ≤72 h video-electroencephalogram (video-EEG)-based primary endpoints (reduction in average daily frequency of focal seizures at end-of-maintenance [EOM] versus end-of-baseline [EOB], patients with ≥50% response). This was unexpected because randomized controlled trial SP0969 (NCT01921205) showed efficacy of lacosamide in patients aged ≥4 to <17 years with uncontrolled focal seizures. SP0969's primary endpoint was based on seizure diary instead of video-EEG, an issue with the latter being inter-reader variability. We evaluated inter-reader agreement in video-EEG interpretation in SP0967, which to our knowledge, are the first such data for very young children with focal seizures from a placebo-controlled trial., Methods: Local investigator and central reader agreement in video-EEG interpretation was analyzed post hoc., Results: Analysis included 105 EOB and 98 EOM video-EEGs. Local investigators and central reader showed poor agreement based on ≥2 focal seizures at EOB (Kappa = 0.01), and fair agreement based on ≥2 focal seizures at EOM (Kappa = 0.23). Local investigator and central reader seizure count interpretations varied substantially, particularly for focal seizures, but also primary generalized and unclassified epileptic seizures, at both timepoints., Interpretation: High inter-reader variability and low inter-reader reliability of the interpretation of seizure types and counts prevent confident conclusion regarding the lack of efficacy of lacosamide in this population. We recommend studies in very young children do not employ video-EEGs exclusively for accurate study inclusion or as an efficacy measure., (© 2024 UCB Biopharma SRL. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)
- Published
- 2024
- Full Text
- View/download PDF
184. Fifteen years of real-world data on the use of vigabatrin in individuals with infantile epileptic spasms syndrome.
- Author
-
Kuchenbuch M, Lo Barco T, Chemaly N, Chiron C, and Nabbout R
- Subjects
- Humans, Female, Infant, Anticonvulsants adverse effects, Treatment Outcome, Spasm drug therapy, Syndrome, Recurrence, Steroids therapeutic use, Vigabatrin, Spasms, Infantile drug therapy, Spasms, Infantile diagnosis
- Abstract
Objective: This study was undertaken to evaluate our treatment algorithm for infantile epileptic spasms syndrome (IESS) used between 2000 and 2018. We initiated vigabatrin (VGB), and steroids were added if the electroclinical response (spasms and electroencephalogram [EEG]) to VGB was not obtained or incomplete., Methods: Individuals with IESS treated with VGB were recruited from our hospital clinical data warehouse based on electronic health records (EHRs) generated since 2009 and containing relevant keywords. We confirmed the diagnosis of IESS. Clinical, EEG, imaging, and biological data were extracted from the EHRs. We analyzed factors associated with short-term response, time to response, relapse, time to relapse of spasms, and the presence of spasms at last follow-up., Results: We collected data from 198 individuals (female: 46.5%, IESS onset: 6 [4.5-10.3] months, follow-up: 4.6 [2.5-7.6] years, median [Q1-Q3]) including 129 (65.2%) with identifiable etiology. VGB was started 17 (5-57.5) days after IESS diagnosis. A total of 113 individuals were responders (57.1% of the cohort), 64 with VGB alone and 38 with VGB further combined with steroids (56.6% and 33.6% of responders, respectively). Among responders, 33 (29%) experienced relapses of spasms, mostly those with later onset of spasms (p = .002) and those who received VGB for <24 months after spasms cessation compared to a longer duration on VGB (45% vs. 12.8%, p = .003). At follow-up, 92 individuals were seizure-free (46.5% of the whole cohort), including 26 free of therapy (13.1%). One hundred twelve individuals (56.6%) were still receiving VGB, with a duration of 3.2 (1.75-5.7) years., Significance: Our sequential protocol introducing VGB then adding steroids is an effective alternative to a combined VGB-steroids approach in IESS. It avoids steroid-related adverse events, as well as those from VGB-steroid combination. According to our data, a period of 7 days seems sufficient to assess VGB response and enables the addition of steroids rapidly if needed. Continuing VGB for 2 years may balance the risk of relapse and treatment-induced adverse events., (© 2023 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.)
- Published
- 2024
- Full Text
- View/download PDF
185. Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus.
- Author
-
Chiron C, Chemaly N, Chancharme L, and Nabbout R
- Subjects
- Infant, Male, Female, Humans, Child, Preschool, Anticonvulsants adverse effects, Retrospective Studies, Treatment Outcome, Seizures drug therapy, Epilepsies, Myoclonic complications, Epilepsies, Myoclonic drug therapy, Status Epilepticus drug therapy
- Abstract
Aim: To evaluate the safety and efficacy of stiripentol initiated before 2 years of age in patients with Dravet syndrome., Method: This was a 30-year, real-world retrospective study. We extracted the data of the 131 patients (59 females, 72 males) who initiated stiripentol before 2 years of age between 1991 and 2021 from the four longitudinal databases of Dravet syndrome available in France., Results: Stiripentol was added to valproate and clobazam (93%) at 13 months and a median dose of 50 mg/kg/day. With short-term therapy (<6 months on stiripentol, median 4 months, median age 16 months), the frequency of tonic-clonic seizures (TCS) lasting longer than 5 minutes decreased (p < 0.01) and status epilepticus (>30 minutes) disappeared in 55% of patients. With long-term therapy (last visit on stiripentol <7 years of age, median stiripentol 28 months, median age 41 months), the frequency of long-lasting TCS continued to decline (p = 0.03). Emergency hospitalizations dropped from 91% to 43% and 12% with short- and long-term therapies respectively (p < 0.001). Three patients died, all from sudden unexpected death in epilepsy. Three patients discontinued stiripentol for adverse events; 55% reported at least one adverse event, mostly loss of appetite/weight (21%) and somnolence (11%). Stiripentol was used earlier, at lower doses, and was better tolerated by patients in the newest database than in the oldest (p < 0.01)., Interpretation: Initiating stiripentol in infants with Dravet syndrome is safe and beneficial, significantly reducing long-lasting seizures including status epilepticus, hospitalizations, and mortality in the critical first years of life., (© 2023 The Authors. Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith Press.)
- Published
- 2023
- Full Text
- View/download PDF
186. Protocol to establish an oviduct epithelial cell line derived from Gallus gallus using Percoll for in vitro validation of recombinant proteins.
- Author
-
Loubser C and Nikitina NV
- Subjects
- Humans, Female, Animals, Recombinant Proteins genetics, Recombinant Proteins metabolism, Epithelial Cells, Chickens, Oviducts metabolism, Povidone, Silicon Dioxide
- Abstract
In vitro validation of therapeutic and recombinant proteins expressed from transgenic chickens is limited by the co-culture of fibroblasts. Here, we present a protocol for isolating pure epithelial cells derived from the magnum tubular glands of the chicken oviduct. We describe steps for preparing solutions and buffers, tissue collection, processing, dissociation, and Percoll density centrifugation to separate the epithelial cells from co-isolated fibroblasts. We then detail procedures for expressing a recombinant IgG antibody in the Percoll-derived epithelial cell line., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
187. A frameshift variant in the melanophilin gene is associated with loss of pigment from shed skin in ball pythons ( Python regius ).
- Author
-
Lederer I, Shahid B, Dao U, Brogdon A, Byrtus H, Delva M, Deva O, Hatfield P, Hertz M, Justice J, Mavor S, Pilbeam E, Rice Z, Simpson A, Temar H, Wynn R, Xhangolli J, Graves C, and Seidel H
- Abstract
Melanophilin is a myosin adaptor required for transporting the pigment melanin within cells. Loss of melanophilin in fish, birds, and mammals causes pigmentation defects, but little is known about the role of melanophilin in non-avian reptiles. Here we show that a frameshift in the melanophilin gene in ball python ( P. regius ) is associated with loss of pigment from shed skin. This variant is predicted to remove the myosin-binding domain of melanophilin and thereby impair transport of melanin-containing organelles. Our study represents the first description of a melanophilin variant in a non-avian reptile and confirms the role of melanophilin across vertebrates., Competing Interests: The authors declare that there are no conflicts of interest present., (Copyright: © 2023 by the authors.)
- Published
- 2023
- Full Text
- View/download PDF
188. Abnormal Spontaneous Blood Oxygenation Level Dependent Fluctuations in Children with Focal Cortical Dysplasias: Initial Findings in Surgically Confirmed Cases.
- Author
-
Dangouloff-Ros V, Jansen JFA, de Jong J, Postma AA, Hoeberigs C, Fillon L, Boisgontier J, Roux CJ, Levy R, Varlet P, Blauwblomme T, Eisermann M, Losito E, Bourgeois M, Chiron C, Nabbout R, Boddaert N, and Backes W
- Subjects
- Humans, Child, Aged, Positron-Emission Tomography methods, Magnetic Resonance Imaging methods, Brain diagnostic imaging, Brain surgery, Brain Mapping methods, Focal Cortical Dysplasia, Drug Resistant Epilepsy
- Abstract
Background: Focal cortical dysplasias (FCD) are a frequent cause of drug-resistant epilepsy in children but are often undetected on structural magnetic resonance imaging (MRI). We aimed to measure and validate the variation of resting state functional MRI (rs-fMRI) blood oxygenation level dependent (BOLD) metrics in surgically proven FCDs in children, to assess the potential yield for detecting and understanding these lesions., Methods: We prospectively included pediatric patients with surgically proven FCD with inconclusive structural MRI and healthy controls, who underwent a ten-minute rs-fMRI acquired at 3T. Rs-fMRI data was pre-processed and maps of values of regional homogeneity (ReHo), degree centrality (DC), amplitude of low frequency fluctuations (ALFF) and fractional ALFF (fALFF) were calculated. The variations of BOLD metrics within the to-be-resected areas were analyzed visually, and quantitatively using lateralization indices. BOLD metrics variations were also analyzed in fluorodeoxyglucose-positron emission tomography (FDG-PET) hypometabolic areas., Results: We included 7 patients (range: 3-15 years) and 6 aged-matched controls (range: 6-17 years). ReHo lateralization indices were positive in the to-be-resected areas in 4/7 patients, and in 6/7 patients in the additional PET hypometabolic areas. These indices were significantly higher compared to controls in 3/7 and 4/7 patients, respectively. Visual analysis revealed a good spatial correlation between high ReHo areas and MRI structural abnormalities (when present) or PET hypometabolic areas. No consistent variation was seen using DC, ALFF, or fALFF., Conclusion: Resting-state fMRI metrics, noticeably increase in ReHo, may have potential to help detect MRI-negative FCDs in combination with other morphological and functional techniques, used in clinical practice and epilepsy-surgery screening., Competing Interests: V.D.-R. was partially funded by GE Healthcare. Other authors have no relevant conflict of interest to disclose., (Thieme. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
189. Preoperative Detection of Subtle Focal Cortical Dysplasia in Children by Combined Arterial Spin Labeling, Voxel-Based Morphometry, Electroencephalography-Synchronized Functional MRI, Resting-State Regional Homogeneity, and 18F-fluorodeoxyglucose Positron Emission Tomography.
- Author
-
Dangouloff-Ros V, Fillon L, Eisermann M, Losito E, Boisgontier J, Charpy S, Saitovitch A, Levy R, Roux CJ, Varlet P, Chiron C, Bourgeois M, Kaminska A, Blauwblomme T, Nabbout R, and Boddaert N
- Subjects
- Humans, Child, Spin Labels, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Magnetic Resonance Imaging methods, Electroencephalography, Fluorodeoxyglucose F18, Focal Cortical Dysplasia
- Abstract
Background: Focal cortical dysplasia (FCD) causes drug-resistant epilepsy in children that can be cured surgically, but the lesions are often unseen by imaging., Objective: To assess the efficiency of arterial spin labeling (ASL), voxel-based-morphometry (VBM), fMRI electroencephalography (EEG), resting-state regional homogeneity (ReHo), 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), and their combination in detecting pediatric FCD., Methods: We prospectively included 10 children for whom FCD was localized by surgical resection. They underwent 3T MR acquisition with concurrent EEG, including ASL perfusion, resting-state BOLD fMRI (allowing the processing of EEG-fMRI and ReHo), 3D T1-weighted images processed using VBM, and FDG PET-CT coregistered with MRI. Detection was assessed visually and by comparison with healthy controls (for ASL and VBM)., Results: Eight children had normal MRI, and 2 had asymmetric sulci. Using MR techniques, FCD was accurately detected by ASL for 6/10, VBM for 5/10, EEG-fMRI for 5/8 (excluding 2 with uninterpretable results), and ReHo for 4/10 patients. The combination of ASL, VBM, and ReHo allowed correct FCD detection for 9/10 patients. FDG PET alone showed higher accuracy than the other techniques (7/9), and its combination with VBM allowed correct FCD detection for 8/9 patients. The detection efficiency was better for patients with asymmetric sulci (2/2 for all techniques), but advanced MR techniques and PET were useful for MR-negative patients (7/8)., Conclusion: A combination of multiple imaging techniques, including PET, ASL, and VBM analysis of T1-weighted images, is effective in detecting subtle FCD in children., (Copyright © Congress of Neurological Surgeons 2022. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
190. An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup.
- Author
-
Diezi L, Dao K, Jullien V, Roussel-Maupetit C, Burton I, André P, Bardinet C, Rothuizen LE, Chtioui H, Manso-Silvan MA, Guittet C, Brunner-Ferber F, Vandenhende F, Chiron C, Granier LA, and Buclin T
- Subjects
- Adult, Humans, Child, Biological Availability, Therapeutic Equivalency, Area Under Curve, Ethosuximide
- Abstract
Ethosuximide, the first-line therapy for childhood absence epilepsy, is currently formulated as a syrup (Zarontin®, Pfizer) with a bitter taste and high sugar content, poorly adapted to children, and a ketogenic diet. The collaborative European FP7 project KIEKIDS aimed at developing an innovative sugar-free, tasteless formulation convenient for pediatric use. This dual Phase-I study evaluated two granule formulations based on lipid multiparticulate (LMP) technology. Two panels of 6 healthy adult volunteers underwent a randomized, placebo-controlled, partly blinded, 3-way cross-over trial, comparing ethosuximide granules A or B with placebo granules and syrup at single 10 mg/kg doses. Corresponding plasma pharmacokinetic profiles of ethosuximide were compared, along with palatability, safety, and tolerability. The LMP granule A proved suboptimal due to bitterness and adherence to beaker walls, while the optimized granule B revealed excellent palatability, similar to placebo granules, and low adherence to glass. The relative bioavailability of granules A versus syrup, based on dose-normalized C
max and AUC0-∞ was 93.7% [90% CI: 76.3-115.1] and 96.1% [91.0-101.5], respectively. For granules B it was 87.6% [81.6-94.0] and 92.5% [88.5-96.6], respectively, with slightly delayed tmax of 0.75 h [0.5-4.05] compared to syrup 0.5 h [0.3-0.8]. Tolerability visual analog scales revealed a trend for statistically non-significant improvement versus syrup at peak (30 min) for transient dizziness (both granules), fatigue (granules A), and anxiety (granules B). The innovative ethosuximide granule formulation B achieves a suitable profile for pediatric use, being sugar-free, tasteless, bioequivalent, and well-tolerated while enabling precise adjustment to body weight., (© 2022 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.)- Published
- 2023
- Full Text
- View/download PDF
191. Overview of therapeutic options for epilepsy.
- Author
-
Kuchenbuch M, Chiron C, and Milh M
- Subjects
- Adolescent, Child, Humans, Child, Preschool, Vigabatrin therapeutic use, Seizures etiology, Prognosis, Anticonvulsants therapeutic use, Spasms, Infantile drug therapy, Epilepsy therapy, Epilepsy drug therapy
- Abstract
Tuberous sclerosis (TSC) epilepsy includes infantile spasms and focal seizures before the age of 2 years, whereas focal seizures are predominant over 2 years and generalized seizures may occasionally be part of Lennox-Gastaut syndrome. The better and earlier the seizure control, the better the child's subsequent cognitive and behavioral prognosis. As for epilepsy of other causes, therapeutic options depend on the type of seizure/epilepsy, age and drug resistance, but there are significant specificities for TSC. (1) As first-line treatment, vigabatrin is unanimously recommended for infantile spasms and focal seizures before 2 years and is also widely used for seizures over 2 years, as are levetiracetam and carbamazepine. (2) If seizures persist (about 40% of children and adolescents), cannabidiol and everolimus, an inhibitor of the mTOR pathway, have recently been approved as adjunctive therapy to the arsenal of antiseizure medications authorized for this age group and to the ketogenic diet. (3) Surgery is an essential treatment option in cases of drug resistance and should be discussed as soon as two treatments have failed. Presurgical investigations and operating techniques have recently progressed spectacularly, for example laser thermocoagulation with stereotactic location. A particularity of TSC is the possibility of sequential interventions on several epileptogenic tubers. (4) Finally, the innovative principle of initiating "pre-seizure" treatment with vigabatrin from the first months of life has just proven effective on the subsequent development of epilepsy in TSC. © 2022 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved., (Copyright © 2022 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
192. GluN2C selective inhibition is a target to develop new antiepileptic compounds.
- Author
-
Gataullina S, Galvani G, Touchet S, Nous C, Lemaire É, Laschet J, Chiron C, Dulac O, Dossi E, Brion JD, Messaoudi S, Alami M, and Huberfeld G
- Subjects
- Animals, Humans, Infant, Mice, Anticonvulsants pharmacology, Anticonvulsants therapeutic use, N-Methylaspartate, Receptors, N-Methyl-D-Aspartate, Seizures etiology, Seizures complications, Epilepsy etiology, Epilepsy complications, Tuberous Sclerosis complications
- Abstract
Objective: Many early-onset epilepsies present as developmental and epileptic encephalopathy associated with refractory seizures, altered psychomotor development, and disorganized interictal cortical activity. Abnormal upregulation of specific N-methyl-d-aspartate receptor (NMDA-R) subunits is being disentangled as one of the mechanisms of severe early-onset epilepsies. In tuberous sclerosis complex (TSC), upregulation of the GluN2C subunit of the NMDA-R with slow deactivation kinetic results in increased neuronal excitation and synchronization., Methods: Starting from an available GluN2C/D antagonist, NMDA-R-modulating compounds were developed and screened using a patch clamp on neuronal culture to select those with the strongest inhibitory effect on glutamatergic NMDA currents. For these selected compounds, blood pharmacokinetics and passage through the blood-brain barrier were studied. We tested the effect of the most promising compounds on epileptic activity in Tsc1
+/- mice brain slices with multielectrode array, and then in vivo at postnatal ages P14-P17, comparable with the usual age at epilepsy onset in human TSC., Results: Using a double-electrode voltage clamp on isolated NMDA currents, we identified the most prominent antagonists of the GluN2C subunit with no effect on GluN2A as a means of preventing side effects. The best compound passing through the blood-brain barrier was selected. Applied in vivo in six Tsc1+/- mice at P14-P17, this compound reduced or completely stopped spontaneous seizures in four of them, and decreased the background activity disorganization. Furthermore, ictal-like discharges stopped on a human brain sample from an infant with epilepsy due to TSC., Interpretation: Subunit-selective inhibition is a valuable target for developing drugs for severe epilepsies resulting from an upregulation of NMDA-R subunit-mediated transmission., (© 2022 International League Against Epilepsy.)- Published
- 2022
- Full Text
- View/download PDF
193. Allelic variation of Escherichia coli outer membrane protein A: Impact on cell surface properties, stress tolerance and allele distribution.
- Author
-
Liao C, Santoscoy MC, Craft J, Anderson C, Soupir ML, and Jarboe LR
- Subjects
- Alleles, Amino Acids metabolism, Bacterial Outer Membrane Proteins metabolism, Escherichia coli genetics, Escherichia coli metabolism, Humans, Leukocyte Elastase metabolism, Surface Properties, Escherichia coli Infections microbiology, Escherichia coli Proteins genetics, Escherichia coli Proteins metabolism, Extraintestinal Pathogenic Escherichia coli genetics
- Abstract
Outer membrane protein A (OmpA) is one of the most abundant outer membrane proteins of Gram-negative bacteria and is known to have patterns of sequence variations at certain amino acids-allelic variation-in Escherichia coli. Here we subjected seven exemplar OmpA alleles expressed in a K-12 (MG1655) ΔompA background to further characterization. These alleles were observed to significantly impact cell surface charge (zeta potential), cell surface hydrophobicity, biofilm formation, sensitivity to killing by neutrophil elastase, and specific growth rate at 42°C and in the presence of acetate, demonstrating that OmpA is an attractive target for engineering cell surface properties and industrial phenotypes. It was also observed that cell surface charge and biofilm formation both significantly correlate with cell surface hydrophobicity, a cell property that is increasingly intriguing for bioproduction. While there was poor alignment between the observed experimental values relative to the known sequence variation, differences in hydrophobicity and biofilm formation did correspond to the identity of residue 203 (N vs T), located within the proposed dimerization domain. The relative abundance of the (I, δ) allele was increased in extraintestinal pathogenic E. coli (ExPEC) isolates relative to environmental isolates, with a corresponding decrease in (I, α) alleles in ExPEC relative to environmental isolates. The (I, α) and (I, δ) alleles differ at positions 203 and 251. Variations in distribution were also observed among ExPEC types and phylotypes. Thus, OmpA allelic variation and its influence on OmpA function warrant further investigation., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
194. Pharmacotherapy for Seizures in Tuberous Sclerosis Complex.
- Author
-
Nabbout R, Kuchenbuch M, Chiron C, and Curatolo P
- Subjects
- Cannabidiol therapeutic use, Humans, MTOR Inhibitors therapeutic use, Seizures physiopathology, Tuberous Sclerosis physiopathology, Vigabatrin therapeutic use, Anticonvulsants therapeutic use, Seizures drug therapy, Seizures epidemiology, Tuberous Sclerosis drug therapy, Tuberous Sclerosis epidemiology
- Abstract
Epilepsy is one of the main symptoms affecting the lives of individuals with tuberous sclerosis complex (TSC), causing a high rate of morbidity. Individuals with TSC can present with various types of seizures, epilepsies, and epilepsy syndromes that can coexist or appear in relation to age. Focal epilepsy is the most frequent epilepsy type with two developmental and epileptic encephalopathies: infantile spasms syndrome and Lennox-Gastaut syndrome. Active screening and early management of epilepsy is recommended in individuals with TSC to limit its consequences and its impact on quality of life, cognitive outcome and the economic burden of the disease. The progress in the knowledge of the mechanisms underlying epilepsy in TSC has paved the way for new concepts in the management of epilepsy related to TSC. In addition, we are moving from traditional "reactive" and therapeutic choices with current antiseizure medications used after the onset of seizures, to a proactive approach, aimed at predicting and preventing epileptogenesis and the onset of epilepsy with vigabatrin, and to personalized treatments with mechanistic therapies, namely mechanistic/mammalian target of rapamycin inhibitors. Indeed, epilepsy linked to TSC is one of the only epilepsies for which a predictive and preventive approach can delay seizure onset and improve seizure response. However, the efficacy of such interventions on long-term cognitive and psychiatric outcomes is still under investigation., (© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2021
- Full Text
- View/download PDF
195. Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome.
- Author
-
Nabbout R, Chemaly N, Chiron C, and Kuchenbuch M
- Subjects
- Anticonvulsants adverse effects, Child, Preschool, Epilepsies, Myoclonic physiopathology, Humans, Infant, Randomized Controlled Trials as Topic, Seizures drug therapy, Seizures physiopathology, Anticonvulsants administration & dosage, Epilepsies, Myoclonic drug therapy
- Abstract
Introduction : Management of individuals with Dravet Syndrome has evolved significantly over the past 10 years. Progress has been made in understanding the pathophysiology, the long-term outcome and possible consequences of inappropriate therapies, new drugs have been approved by the regulatory authorities and patients and families expressed their needs beyond seizures' control. Areas covered : The authors aimed at providing an overview of the main antiseizure medications used in Dravet syndrome with a particular focus on safety considerations. As the highly active phase of seizures takes place before the age of 5 years, the characteristics of antiseizure medications in infancy and childhood have also been considered due to their impact on antiseizure medication safety. Expert opinion : Recent treatments, evaluated via randomized clinical trials, are promising in terms of efficacy and safety in individuals with DS. However, the balance between expected benefits and risks taken must be accurately assessed on an individual basis. There is a lack of data to understand the needs of patients and families, a major point particularly in this population, where the evaluation of efficacy and safety beyond seizures is difficult due to cognitive delay and behavioral disorders and where this evaluation is coming almost exclusively from caregivers.
- Published
- 2021
- Full Text
- View/download PDF
196. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
- Author
-
Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, Stephani U, Laux L, Wirrell E, Knupp K, Chiron C, Farfel G, Galer BS, Morrison G, Lock M, Agarwal A, and Auvin S
- Subjects
- Adolescent, Anticonvulsants therapeutic use, Child, Child, Preschool, Dioxolanes therapeutic use, Double-Blind Method, Drug Resistant Epilepsy etiology, Drug Therapy, Combination methods, Epilepsies, Myoclonic complications, Female, Humans, Male, Drug Resistant Epilepsy drug therapy, Epilepsies, Myoclonic drug therapy, Fenfluramine therapeutic use, Selective Serotonin Reuptake Inhibitors therapeutic use
- Abstract
Importance: Fenfluramine treatment may reduce monthly convulsive seizure frequency in patients with Dravet syndrome who have poor seizure control with their current stiripentol-containing antiepileptic drug regimens., Objective: To determine whether fenfluramine reduced monthly convulsive seizure frequency relative to placebo in patients with Dravet syndrome who were taking stiripentol-inclusive regimens., Design, Setting, and Participants: This double-blind, placebo-controlled, parallel-group randomized clinical trial was conducted in multiple centers. Eligible patients were children aged 2 to 18 years with a confirmed clinical diagnosis of Dravet syndrome who were receiving stable, stiripentol-inclusive antiepileptic drug regimens., Interventions: Patients with 6 or more convulsive seizures during the 6-week baseline period were randomly assigned to receive fenfluramine, 0.4 mg/kg/d (maximum, 17 mg/d), or a placebo. After titration (3 weeks), patients' assigned dosages were maintained for 12 additional weeks. Caregivers recorded seizures via a daily electronic diary., Main Outcomes and Measures: The primary efficacy end point was the change in mean monthly convulsive seizure frequency between fenfluramine and placebo during the combined titration and maintenance periods relative to baseline., Results: A total of 115 eligible patients were identified; of these, 87 patients (mean [SD], age 9.1 [4.8] years; 50 male patients [57%]; mean baseline frequency of seizures, approximately 25 convulsive seizures per month) were enrolled and randomized to fenfluramine, 0.4 mg/kg/d (n = 43) or placebo (n = 44). Patients treated with fenfluramine achieved a 54.0% (95% CI, 35.6%-67.2%; P < .001) greater reduction in mean monthly convulsive seizure frequency than those receiving the placebo. With fenfluramine, 54% of patients demonstrated a clinically meaningful (≥50%) reduction in monthly convulsive seizure frequency vs 5% with placebo (P < .001). The median (range) longest seizure-free interval was 22 (3.0-105.0) days with fenfluramine and 13 (1.0-40.0) days with placebo (P = .004). The most common adverse events were decreased appetite (19 patients taking fenfluramine [44%] vs 5 taking placebo [11%]), fatigue (11 [26%] vs 2 [5%]), diarrhea (10 [23%] vs 3 [7%]), and pyrexia (11 [26%] vs 4 [9%]). Cardiac monitoring demonstrated no clinical or echocardiographic evidence of valvular heart disease or pulmonary arterial hypertension., Conclusions and Relevance: Fenfluramine demonstrated significant improvements in monthly convulsive seizure frequency in patients with Dravet syndrome whose conditions were insufficiently controlled with stiripentol-inclusive antiepileptic drug regimens. Fenfluramine was generally well tolerated. Fenfluramine may represent a new treatment option for Dravet syndrome., Trial Registration: ClinicalTrials.gov identifier: NCT02926898.
- Published
- 2020
- Full Text
- View/download PDF
197. Drug Development for Rare Paediatric Epilepsies: Current State and Future Directions.
- Author
-
Auvin S, Avbersek A, Bast T, Chiron C, Guerrini R, Kaminski RM, Lagae L, Muglia P, and Cross JH
- Subjects
- Animals, Child, Drug Development, Epileptic Syndromes genetics, Humans, Epileptic Syndromes drug therapy, Orphan Drug Production, Rare Diseases drug therapy
- Abstract
Rare diseases provide a challenge in the evaluation of new therapies. However, orphan drug development is of increasing interest because of the legislation enabling facilitated support by regulatory agencies through scientific advice, and the protection of the molecules with orphan designation. In the landscape of the rare epilepsies, very few syndromes, namely Dravet syndrome, Lennox-Gastaut syndrome and West syndrome, have been subject to orphan drug development. Despite orphan designations for rare epilepsies having dramatically increased in the past 10 years, the number of approved drugs remains limited and restricted to a handful of epilepsy syndromes. In this paper, we describe the current state of orphan drug development for rare epilepsies. We identified a large number of compounds currently under investigation, but mostly in the same rare epilepsy syndromes as in the past. A rationale for further development in rare epilepsies could be based on the match between the drug mechanisms of action and the knowledge of the causative gene mutation or by evidence from animal models. In case of the absence of strong pathophysiological hypotheses, exploratory/basket clinical studies could be helpful to identify a subpopulation that may benefit from the new drug. We provide some suggestions for future improvements in orphan drug development such as promoting paediatric drug investigations, better evaluation of the incidence and the prevalence, together with the natural history data, and the development of new primary outcomes.
- Published
- 2019
- Full Text
- View/download PDF
198. Perception of impact of Dravet syndrome on children and caregivers in multiple countries: looking beyond seizures.
- Author
-
Nabbout R, Auvin S, Chiron C, Thiele E, Cross H, Scheffer IE, Schneider AL, Guerrini R, and Williamson N
- Subjects
- Adolescent, Adult, Australia, Child, Child, Preschool, Cross-Cultural Comparison, Epilepsies, Myoclonic complications, Female, Humans, Italy, Male, Middle Aged, Parent-Child Relations, Qualitative Research, Quality of Life, United Kingdom, United States, Caregivers psychology, Epilepsies, Myoclonic psychology
- Abstract
Aim: To assess the relevance and generalizability across countries of concepts of the impact of Dravet syndrome beyond seizures, as recognized by families., Method: Caregivers of children with Dravet syndrome in four countries (Australia [n=8]; USA, UK, and Italy [all n=4]) participated in 1-hour qualitative telephone interviews, identifying key Dravet syndrome concepts. Interviews were recorded, transcribed, and, where necessary, translated into English for thematic analysis. Conceptual saturation was assessed and findings compared to the previously developed French conceptual disease model., Results: The most common seizure types reported by caregivers were tonic-clonic, absence, or focal-impaired awareness (localized/partial). Fever and physical activity were the most commonly reported triggers. Patient-relevant impacts included impairment in cognition, motor skills, communication, social skills, and behavioural functioning. Caregivers consistently reported negative social, physical, and family impacts. Concepts identified in the interviews showed similarity with the French conceptual model. Minor differences between countries are likely to reflect variations in health care systems., Interpretation: Findings in Italy, Australia, UK, and USA confirm that the key impacts of Dravet syndrome on children and caregivers identified in France are generalizable across countries. Key symptom and impact concepts relevant to children and parents should be targeted as critical outcomes in new therapy evaluations., What This Paper Adds: Relevance of the impact of Dravet syndrome on children and caregivers was confirmed across countries. Patient and caregiver-relevant Dravet syndrome impacts contribute to poorer health-related quality of life. Indirect seizure impacts were reported to be as important as direct impacts. Country-specific differences in concepts probably reflect differences in health care systems., (© 2019 Mac Keith Press.)
- Published
- 2019
- Full Text
- View/download PDF
199. Which Protocol for Milrinone to Treat Cerebral Vasospasm Associated With Subarachnoid Hemorrhage?
- Author
-
Crespy T, Heintzelmann M, Chiron C, Vinclair M, Tahon F, Francony G, and Payen JF
- Subjects
- Adult, Female, Humans, Infusions, Intra-Arterial, Male, Middle Aged, Milrinone administration & dosage, Milrinone adverse effects, Retrospective Studies, Treatment Outcome, Vasodilator Agents administration & dosage, Vasodilator Agents adverse effects, Milrinone therapeutic use, Subarachnoid Hemorrhage complications, Vasodilator Agents therapeutic use, Vasospasm, Intracranial drug therapy, Vasospasm, Intracranial etiology
- Abstract
Background: Milrinone has emerged as an option to treat delayed cerebral ischemia after subarachnoid hemorrhage. However, substantial variation exists in the administration of this drug. We retrospectively assessed the effectiveness of 2 protocols in patients with angiographically proven cerebral vasospasm., Methods: During 2 successive periods, milrinone was administered using either a combination of intra-arterial milrinone infusion followed by intravenous administration until day 14 after initial bleeding (IA+IV protocol), or a continuous intravenous milrinone infusion for at least 7 days (IV protocol). The primary endpoint was the reversion rate of vasospastic arterial segments following the first IA infusion of milrinone (IA+IV protocol) compared with the reversion rate during the first week of IV infusion (IV protocol)., Results: There were 24 and 77 consecutive patients in IA+IV and IV protocols, respectively. The reversion rate was comparable between the 2 protocols: 71% (95% confidence interval [CI], 59%-83%) in the IA+IV protocol versus 64% (95% CI, 58%-71%) in the IV protocol (P=0.36). Rescue procedures for persistence or recurrence of vasospasm, that is, mechanical angioplasty and/or IA milrinone infusion, were similar between the 2 protocols. Patients with a good neurological outcome at 1 year, that is, modified Rankin Scale scores 0-2, were comparable between the 2 protocols. Side effects of milrinone were uncommon and equally distributed within the 2 protocols., Conclusions: These findings indicate that a continuous IV infusion of milrinone was as efficient as combined IA+IV infusion and suggest that this modality could be considered as a first easy-to-use option to treat patients with CVS.
- Published
- 2019
- Full Text
- View/download PDF
200. Stiripentol for the treatment of seizures associated with Dravet syndrome.
- Author
-
Chiron C
- Subjects
- Epilepsies, Myoclonic complications, Humans, Seizures etiology, Anticonvulsants pharmacology, Dioxolanes pharmacology, Epilepsies, Myoclonic drug therapy, Seizures drug therapy
- Abstract
Introduction: Stiripentol is an orphan drug approved for the treatment of seizures associated with Dravet syndrome (since 2007 in Europe). Therapeutic options recently grew in this rare and severe early-onset epilepsy with the approval of stiripentol and cannabidiol in 2018 in the US and the positive trials just completed with fenfluramine. Areas covered: First, the short-term efficacy of stiripentol as adjunctive therapy to clobazam and valproate, which was discovered by serendipity thanks to a basket study and then confirmed in 1998 despite the small number of samples in phase III trials. Second, the further observational series worldwide, which showed sustained efficacy and satisfactory tolerability for up to 20 year exposure. Third, why it took more than 20 years for stiripentol be approved in a number of countries despite these extensive data: drug-drug interactions between stiripentol and comedication will be addressed, as well as the experimental and pharmacogenetic data which support the anticonvulsant effect of stiripentol per se. Expert opinion: Considering current and future competitors (cannabidiol and fenfluramine), efficacy seems lower for cannabidiol and seizure freedom seems occasionally be obtained with fenfluramine. Additionally, stiripentol could be especially useful in two critical conditions of the disease, very young age (<2 years) and convulsive status epilepticus.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.